Clinical trial NCT04713631 - References

Crohn's Disease — Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease

Citation(s)

•   Hou L, Huang H
  Immune suppressive properties of artemisinin family drugs. Pharmacol Ther. 2016 Oct;166:123-7. doi: 10.1016/j.pharmthera.2016.07.002. Epub 2016 Jul 10.
•   Suskind DL, Wahbeh G, Burpee T, Cohen M, Christie D, Weber W
  Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. J Pediatr Gastroenterol Nutr. 2013 Mar;56(3):277-9. doi: 10.1097/MPG.0b013e318276977d.
•   Yang Z, Ding J, Yang C, Gao Y, Li X, Chen X, Peng Y, Fang J, Xiao S
  Immunomodulatory and anti-inflammatory properties of artesunate in experimental colitis. Curr Med Chem. 2012;19(26):4541-51. doi: 10.2174/092986712803251575.

Phase 2a Randomised Double-blind Placebo-controlled Trial to Assess Safety, Efficacy of Artesunate & Curcumin in Crohn's Disease Patients, Who Continue to Have Mild to Moderate Disease Activity on an Adequate Dose of Azathioprine

Details for clinical trial NCT04713631